Emerging diuretics for the treatment of heart failure

Bibliography

• Rosamond W, Flegal K, Friday G. Heart disease and stroke statistics – 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115(5):e69-171
   PubMed Web of Science ®Google Scholar
• Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related hospitalization in the US, 1979 to 2004. J Am Coll Cardiol 2008;52(6):428-34
   PubMed Web of Science ®Google Scholar
• Abraham WT, Fonarow GC, Albert NM. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008;52(5):347-56
   PubMed Web of Science ®Google Scholar
• Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113(5):671-8
   PubMed Web of Science ®Google Scholar
• De Luca L, Klein L, Udelson JE, et al. Hyponatremia in patients with heart failure. Am J Cardiol 2005;96(12A):19L-23L
   PubMed Web of Science ®Google Scholar
• Klein L, O'Connor CM, Leimberger JD, et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005;111(19):2454-60
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Rossi JS, Cotts W, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007;167(18):1998-2005
   PubMed Web of Science ®Google Scholar
• Yamane Y. Plasma ADH level in patients with chronic congestive heart failure. Jpn Circ J 1968;32(5):745-59
   PubMedGoogle Scholar
• Goldsmith SR,Francis GS, Cowley AW Jr, Levine TD, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983;1(6):1385-90
   PubMed Web of Science ®Google Scholar
• Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82(5):1724-9
   PubMed Web of Science ®Google Scholar
• Nakamura T, Funayama H, Yoshimura A, et al. Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. Int J Cardiol 2006;106(2):191-5
   PubMed Web of Science ®Google Scholar
• Rouleau JL, Packer M, Moyé L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994;24(3):583-91
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol 2000;391(1-2):39-48
   PubMed Web of Science ®Google Scholar
• Tahara A, Tomura Y, Wada K, et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998;38(1):198-205
   PubMed Web of Science ®Google Scholar
• Kalra PR, Anker SD, Coats AJ. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res 2001;51(3):495-509
   PubMed Web of Science ®Google Scholar
• Ohnishi A, Orita Y, Takagi N et al. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J Pharmacol Exp Ther 1995;272(2):546-51
   PubMed Web of Science ®Google Scholar
• Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003;146(1):9-18
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia. N Engl J Med 2006;355(20):2099-112
   Google Scholar
• Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291(16):1963-71
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107(21):2690-6
   PubMed Web of Science ®Google Scholar
• Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37(1):182-91
   PubMed Web of Science ®Google Scholar
• Zeltser D, Rosansky S, van Rensburg H, et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007;27(5):447-57
   PubMed Web of Science ®Google Scholar
• Udelson JE, Smith WB, Hendrix GH, et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104(20):2417-23
   PubMed Web of Science ®Google Scholar
• Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287(3):860-7
   PubMed Web of Science ®Google Scholar
• Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther 2000;292(1):288-94
   PubMed Web of Science ®Google Scholar
• Udelson JE, McGrew FA, Flores E, et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007;49(22):2151-9
   PubMed Web of Science ®Google Scholar
• Mehra MR, Rockman HA, Greenberg BH. Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America: Washington, DC, September 16-19, 2007. J Am Coll Cardiol 2008;51(3):320-7
   PubMedGoogle Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297(12):1319-31
   PubMed Web of Science ®Google Scholar
• Gellai M, Schreiner GF, Ruffolo RR Jr, Fletcher T, DeWolf R, Brooks DP. CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity. J Pharmacol Exp Ther 1998;286(3):1191-6
   PubMed Web of Science ®Google Scholar
• Wilcox CS, Welch WJ, Schreiner GF, Belardinelli L. Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol 1999;10(4):714-20
   PubMed Web of Science ®Google Scholar
• Sun D, Samuelson LC, Yang T, et al. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 2001;98(17):9983-8
   PubMed Web of Science ®Google Scholar
• Jackson EK, Kost CK Jr, Herzer WA, Smits GJ, Tofovic SP. A(1) receptor blockade induces natriuresis with a favorable renal hemodynamic profile in SHHF/Mcc-fa(cp) rats chronically treated with salt and furosemide. J Pharmacol Exp Ther 2001;299(3):978-87
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, Skettino SL, Wolff A, et al. Effects of BG9719 (CVT-124), an A1-Adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol, 2000;35(1):56-9
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy. Circulation 2002;105(11):1348-53
   Google Scholar
• Greenberg B, Thomas I, Banish D, et al. Effects of Multiple Oral Doses of an A1 Adenosine Antagonist, BG9928, in Patients With Heart Failure: Results of a Placebo-Controlled, Dose-Escalation Study. J Am Coll Cardiol 2007;50(7):600-6
   PubMed Web of Science ®Google Scholar
• Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC, CKI-201 and CKI 202 Investigators. The Effects of KW-3902, an Adenosine A1-Receptor Antagonist,on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance. J Am Coll Cardiol 2007;50(16):1551-60
   PubMed Web of Science ®Google Scholar
• Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S. The Effect of KW-3902, an Adenosine A1 Receptor Antagonist, on Renal Function and Renal Plasma Flow in Ambulatory Patients With Heart Failure and Renal Impairment. J Card Fail 2007;13(8):609-17
   PubMed Web of Science ®Google Scholar
• Cotter G, Dittrich HC, Weatherley BD, et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008;14(8):631-40
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293(15):1900-5
   PubMed Web of Science ®Google Scholar
• Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111(12):1487-91
   PubMed Web of Science ®Google Scholar
• Elsner D,Muders F, Müntze A, kromer EP, Forssmann WG, Riegger GA. Efficacy of prolonged infusion of urodilatin [ANP-(95-126)] in patients with congestive heart failure. Am Heart J 1995;129(4):766-73
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Muders F, Müntze A, Kromer EP, Forssmann WG, Riegger GA. Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J 2005;150(6):1239
   PubMed Web of Science ®Google Scholar
• Mitrovic V, Seferovic PM, Simeunovic D. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006;27(23):2823-32
   PubMed Web of Science ®Google Scholar
• Luss H, Mitrovic V, Seferovic PM. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 2008;155(6):1012 e1-8
   PubMed Web of Science ®Google Scholar
• Bart BA, Boyle A, Bank AJ. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005;46(11):2043-6
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Guglin ME, Saltzberg MT. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49(6):675-83
   PubMed Web of Science ®Google Scholar